Abstract
Background
Selective serotonin reuptake inhibitors (SSRIs) inhibit platelet function, and use of these drugs has been associated with bleeding events. The objective of this study was to examine whether the requirement for red blood cell transfusion was increased following preoperative use of SSRIs among patients undergoing coronary artery bypass grafting (CABG).
Methods
A population-based cohort study of transfusion requirements (red blood cells, fresh frozen plasma, and/or platelets) was conducted among patients undergoing CABG at either Aalborg or Skejby Hospitals between 1 January 1998 and 31 December 2003. All prescriptions for antidepressants, including SSRIs, filled before the date of admission for CABG were identified using prescription databases. Patients were categorized according to use of antidepressants (never users, current users [<90 days before admission for CABG], and former users). Antidepressants were classified according to their action on serotonin and norepinephrine reuptake mechanisms. Relative risk (RR) for transfusion were adjusted for: age; sex; preoperative use of platelet inhibitors (low-dose aspirin [acetylsalicylic acid], clopidogrel, and dipyridamole), NSAIDs and oral anticoagulants; place of surgery; extracorporeal circulation; concomitant valve surgery; and Charlson comorbidity index score.
Results
There were 124 (3.5%) current users of SSRIs among 3454 patients. Adjusted RRs for transfusion among current users of SSRIs, users of nonselective serotonin reuptake inhibitor antidepressants, and users of other antidepressants were 1.1 (95% CI 0.9, 1.3), 0.9 (95% CI 0.6, 1.3), and 1.0 (95% CI 0.7, 1.5), respectively, when compared with never users of any type of antidepressant. The adjusted RR among former SSRI users was 1.0 (95% CI 0.7, 1.4). Risk of re-exploration for bleeding and mortality within 30 days did not differ according to the examined drug-exposure categories.
Conclusion
Preoperative use of SSRIs was not associated with any substantially increased requirement for allogeneic red blood cell transfusion among patients undergoing CABG. The main strengths of this study are its relatively large size, the use of prospectively collected data obtained from population-based databases with complete follow-up, and the ability to examine specific types of antidepressants. The limitations include a lack of detailed clinical data regarding other factors that may influence transfusion requirements.
Similar content being viewed by others
References
Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004; 8: 267–81.
Engoren MC, Habib RH, Zacharias A, et al. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg 2002; 74: 1180–6.
Magovern JA, Sakert T, Benckart DH, et al. A model for predicting transfusion after coronary artery bypass grafting. Ann Thorac Surg 1996; 61: 27–32.
Serebruany VL, Gurbel PA, O’Connor CM. Platelet inhibition by sertraline and n-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43: 453–61.
Hergovich N, Aigner M, Eichler H-G, et al. Paroxetine decreases platelet serotonin storage and platelet dysfunction in human beings. Clin Pharmacol Ther 2000; 68: 435–42.
Dalton SO, Johansen C, Mellemkjær L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med 2003; 163: 59–64.
van Walraven V, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001; 323: 655–8.
Meijer WEE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164: 2367–70.
Movig KLL, Janssen WHE, de Malefijt J, et al. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med 2003; 163: 2354–8.
Ford DE, Mead LA, Chang PP, et al. Depression is a risk factor for coronary artery disease in men. Arch Intern Med 1998; 158: 1422–6.
Zellweger MJ, Osterwalder RH, Langewitz W, et al. Coronary artery disease and depression. Eur Heart J 2004; 25: 3–9.
Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93: 1976–80.
Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263–8.
Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997; 340: 249–58.
Transfusion Medicin. Quality assurance databases [online]. Available from URL: http://http://www.dtdb.dk [Accessed 2005 Jul 8].
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83.
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613–9.
McNutt LA, Wu C, Xue X, et al. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003; 157: 940–3.
Yaryura-Tobias JA, Kirschen H, Ninan P, et al. Fluoxetine and bleeding in obsessive-compulsive disorder [letter]. Am J Psychiatry 1991; 148: 949.
Ottervanger JP, Stricker BHC, Huls J, et al. Bleeding attributed to intake of paroxetine [letter]. Am J Psychiatry 1994; 151: 781–2.
Layton D, Clark DW, Pearce GL, et al. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001; 57: 167–76.
Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91: 119–28.
Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270: 1819–25.
Monster TBM, Johnsen SP, Olsen ML, et al. Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Med 2004; 117: 732–7.
Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhytmia Suppression Trial (CAST) studies. J Clin Psychiatry 1994; 55 Suppl. A: 83–7.
Stover EP, Siegel LC, Parks R, et al. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines a 24-institution study. Anesthesiology 1998; 88: 327–33.
Kuduvalli M, Oo AY, Newall N, et al. Effect of peri-operative red blood cell transfusion on 30-day and 1-year mortality following coronary artery bypass surgery. Eur J Cardiothorac Surg 2005; 27: 592–8.
Acknowledgments
This study was funded by Nordjyllands Amts Forskningsudvalg. None of the authors have any conflicts of interest relevant to the contents of this manuscript.
H.T. Sørensen has received an unrestricted grant from Lunbeck A/S for pharmacoepidemiologic research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Andreasen, J.J., Riis, A., Elisabeth Hjortdal, V. et al. Effect of Selective Serotonin Reuptake Inhibitors on Requirement for Allogeneic Red Blood Cell Transfusion Following Coronary Artery Bypass Surgery. Am J Cardiovasc Drugs 6, 243–250 (2006). https://doi.org/10.2165/00129784-200606040-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00129784-200606040-00004